| Literature DB >> 30457485 |
Mizuki Nishino1, Hiroto Hatabu1, F Stephen Hodi1.
Abstract
Cancer immunotherapy using immune-checkpoint inhibitors has emerged as an effective treatment option for a variety of advanced cancers in the past decade. Because of the distinct mechanisms of immunotherapy that activate the host immunity to treat cancers, unconventional immune-related phenomena are encountered in terms of tumor response and progression, as well as drug toxicity. Imaging plays an important role in objectively characterizing immune-related tumor responses and progression and in detecting and monitoring immune-related adverse events. Moreover, emerging data suggest a promise for molecular imaging that can visualize the specific target molecules involved in immune-checkpoint pathways. In this article, the background and current status of cancer immunotherapy are summarized, and the current methods for imaging evaluations of immune-related responses and toxicities are reviewed along with their limitations and pitfalls. Emerging approaches with molecular imaging are also discussed as a future direction to address unmet needs. © RSNA, 2018.Entities:
Mesh:
Year: 2018 PMID: 30457485 PMCID: PMC6312436 DOI: 10.1148/radiol.2018181349
Source DB: PubMed Journal: Radiology ISSN: 0033-8419 Impact factor: 11.105